RBC Capital analyst Leonid Timashev raised the firm’s price target on Axsome Therapeutics (AXSM) to $219 from $212 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Reaffirming Axsome Therapeutics as a Buy on Robust Commercial Growth and Advancing Late‑Stage Pipeline, With a Raised $260 Price Target
- Axsome Therapeutics price target raised to $260 from $200 at H.C. Wainwright
- Axsome Therapeutics price target raised to $223 from $148 at Piper Sandler
- Axsome Therapeutics initiate FORWARD Phase 3 trial of AXS-14
- Axsome Therapeutics price target raised to $209 from $157 at Baird